Is gene editing the potential single-treatment solution for high cholesterol?
-
By
-
Lauran Neergaard
-
February 11, 2026
Clinical Scorecard: Is gene editing the potential single-treatment solution for high cholesterol?
At a Glance
| Category | Detail |
|---|---|
| Condition | High cholesterol, specifically elevated LDL cholesterol and triglycerides |
| Key Mechanisms | Gene editing (CRISPR) to switch off genes ANGPTL3 or PCSK9 in liver cells to reduce cholesterol production |
| Target Population | People at high risk from uncontrolled cholesterol, including those with inherited high cholesterol |
| Care Setting | Specialized clinical trial settings currently; potential future outpatient or preventive cardiology care |
Key Highlights
- Early-stage gene-editing studies show a single infusion can reduce LDL cholesterol and triglycerides by about 50%.
- Gene editing targets genes ANGPTL3 and PCSK9, naturally associated with very low cholesterol in some individuals.
- Long-term safety and efficacy remain unknown; gene editing is considered permanent but requires further large-scale studies.
Guideline-Based Recommendations
Diagnosis
- Assess LDL cholesterol levels to identify high-risk individuals.
- Consider genetic factors influencing cholesterol metabolism.
Management
- Lifestyle modifications: heart-healthy diet, physical activity, weight management, smoking cessation, adequate sleep.
- Pharmacologic treatments: statins as first-line therapy; other pills or injected medicines if statins insufficient or not tolerated.
- Gene-editing therapies currently experimental and limited to clinical trials for high-risk patients.
Monitoring & Follow-up
- Regular lipid profile monitoring to assess LDL and triglyceride levels.
- Monitor liver function and potential side effects during gene-editing trials.
- Long-term follow-up needed for gene-editing recipients to evaluate durability and safety.
Risks
- Potential liver irritation or inflammation from gene-editing delivery particles.
- Unknown long-term safety and off-target gene-editing effects.
- Challenges in adherence to lifelong cholesterol-lowering medications.
Patient & Prescribing Data
Adults with high LDL cholesterol at high risk for cardiovascular disease, including those with genetic predispositions
Gene-editing treatments have shown promising LDL and triglyceride reductions in small early trials; currently investigational and not widely available.
Clinical Best Practices
- Prioritize lifestyle interventions and established pharmacologic therapies for cholesterol management.
- Consider gene-editing therapies only within controlled clinical trials for eligible high-risk patients.
- Educate patients on the importance of adherence to current cholesterol-lowering treatments and lifestyle changes.
- Monitor patients closely for side effects and efficacy when using novel gene-editing approaches.
References
- New England Journal of Medicine study on ANGPTL3 gene editing
- American Heart Association cholesterol guidelines
- CRISPR Therapeutics and Verve Therapeutics gene-editing trials
Based on findings from:
Could gene editing offer the one-time fix for artery-clogging cholesterol?
Lauran Neergaard. Associated Press Health, 2026.
https://apnews.com/article/cholesterol-heart-attack-ldl-gene-editing-crispr-7aa18fea7484be8d3de9e00f3e2b01d6
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
